Bryan Garnier - Novo Nordisk (novob) NOVO NORDISK: On a long-term growth path | BUY vs. NEUTRAL | DKK490 VS. DKK462 (+9%)

Report

Bryan Garnier

Eric Le Berrigaud

NOVO NORDISK: On a long-term growth path | BUY vs. NEUTRAL | DKK490 VS. DKK462 (+9%)

NOVO NORDISK - BUY vs. NEUTRAL | DKK490 VS. DKK462 (+9%)
On a long-term growth path

Nothing preventing Novo Nordisk from growing
Semaglutide is more than a platform in a drug
High visibility on double-digit core EPS growth over 2022-2025

04/02/2021 4 EN

Underlying

Novo Nordisk

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Eric Le Berrigaud

Other Reports on these Companies

New Street Research

Novo - Negative Mix A Major Concern (SELL, TP DKK350, 15pgs)

We have rebuilt our Wegovy & Ozempic models for volume, price & mix to account for the divergent dynamics by channel. We show that 1) Ozempic volume forecasts remain too high and NRx has now turned negative, 2) Mix is set to worsen dramatically for Ozempic such that 2027 group EPS growth is 0% on our numbers, 3) The Wegovy inflection implied in our forecasts is likely best case scenario w.r.t compounding & CVS, yet we are at the low end of guidance. We are modestly below cons. sales in 2025&26 with our optimistic assumptions but 14% below in 2027 due to our analysis on channel mix, IRA & prici...

EUR 4446.50

14h / 15m 14h / 15m 1 EN

New Street Research

MFN Drug Pricing - Impact and Implementation (Thematic, 5pgs)

Ahead of today’s signing of an Executive Order to introduce a Most Favoured Nation approach to drug pricing in the US, we show that net pricing in the EU is c.50% lower than in the US & which companies have most to lose from MFN. We also show that, in reality,

EUR 4446.50

May 12, 2025 May 12, 2025 1 EN

New Street Research

Novo - Worrying Times (SELL, TP DKK350 [460], 13pgs)

Following the orfo’ P3 data, latest Wegovy scrips & rapidly faltering Ozempic growth, we conduct a wholesale review of our obesity market model, Wegovy & Ozempic scrip models & our Novo financial model. The outcome of this analysis is that we downgrade our 2030 sales by 20% and EPS by 24%. We now assume Novo only achieve a 25% obesity market share by 2030. We are 19% below consensus sales & 23% below EPS in 2030. We also provide a detailed hypothesis as to why US obesity demand growth is so lacklustre & conclude demand growth will be slow in the absence of Medicare approval. PT cut to DKK350 &...

EUR 4446.50

April 22, 2025 April 22, 2025 1 EN

Cinclus Pharma: start of phase 3 reiterated for Q3'25

Cinclus Pharma reported its Q1 results which focused on balance sheet items and a recap of corporate achievements for the quarter, with a cash position at SEK523.9m and an EBIT at SEK(47.519m). With the current cash position and operational cash burn, we forecast a runway into H1 2027. On the opera

14h / 5m 14h / 5m 1 EN

Mahaut Arnaud ... (+3)

Mahaut Arnaud
Paul de Froment
Thomas Mordelle

HydrogenPro: LONGi Hydrogen to invest NOK70m

HydrogenPro announced yesterday that LONGi Hydrogen has obtained the necessary Overseas Direct Investment (ODI) approval in China to invest NOK70m in the company. This follows an announcement made in December 2024 whereby HydrogenPro had secured (i) NOK70m in new equity from its existing strategic

14h / 23m 14h / 23m 1 EN

Clement Genelot

Clement Genelot

Just Eat Takeaway: tender to the offer

Following the publication of the offer memorandum yesterday by Prosus and the launch of the tender offer today until 29th July, we have withdrawn our Neutral rating and advise shareholders to tender their shares to the offer.1/ We consider the offer as generous with implied c.11.5x EV/EBITDA 2025e

14h / 41m 14h / 41m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

NOVO NORDISK: On a long-term growth path | BUY vs. NEUTRAL | DKK490 VS. DKK462 (+9%)

Novo - Negative Mix A Major Concern (SELL, TP DKK350, 15pgs)

MFN Drug Pricing - Impact and Implementation (Thematic, 5pgs)

Novo - Worrying Times (SELL, TP DKK350 [460], 13pgs)

Cinclus Pharma: start of phase 3 reiterated for Q3'25

HydrogenPro: LONGi Hydrogen to invest NOK70m

Just Eat Takeaway: tender to the offer

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe